Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL 73 Days Sales Outstanding is 36.51 as of Jun. 2026, which is 23% above its 10-year median of 29.66. GuruFocus rates ASX:ACL with a GF Score™ of 73/100 and a GF Value™ of A$2.95 (Fairly Valued). The stock has 9 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 85.64% on this metric.
The historical rank and industry rank for Australian Clinical Labs's Days Sales Outstanding or its related term are showing as below:
ASX:ACL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.11 Med: 29.66 Max: 34.18
Current: 34.18
During the past 7 years, Australian Clinical Labs's highest Days Sales Outstanding was 34.18. The lowest was 20.11. And the median was 29.66.
ASX:ACL's Days Sales Outstanding is ranked better than 85.64% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.76
vs ASX:ACL: 34.18
Australian Clinical Labs's Days Sales Outstanding
declined
from Jun. 2025 (38.74) to Jun. 2026 (36.51).
Australian Clinical Labs (ASX:ACL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Australian Clinical Labs Days Sales Outstanding Related Terms
Australian Clinical Labs Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Australian Clinical Labs's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs Days Sales Outstanding Chart
ASX:ACL vs TMO, DHR, NTRA: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's Days Sales Outstanding falls into.
Australian Clinical Labs Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs (ASX:ACL) has a Days Sales Outstanding of 36.51 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Australian Clinical Labs and its competitors. This is 23% above median its historical median of 29.66. Over the past decade, Australian Clinical Labs' Days Sales Outstanding has ranged from 20.11 to 34.18. According to the industry distribution chart, Australian Clinical Labs ranks #29 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 14.4%.
Is Australian Clinical Labs' Days Sales Outstanding too high?
Australian Clinical Labs' current Days Sales Outstanding of 36.51 is 23% above median its 10-year median of 29.66. Over the past 10 years, this metric has ranged from a low of 20.11 to a high of 34.18. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.76. Australian Clinical Labs' value of 36.51 is 46.1% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #29 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Australian Clinical Labs has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #29 out of 202 companies for Days Sales Outstanding. This places Australian Clinical Labs in the top 14% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 67.76. Australian Clinical Labs' value of 36.51 is 46.1% below this benchmark. Historically, Australian Clinical Labs' own Days Sales Outstanding has ranged from 20.11 to 34.18 over the past decade. While the company's 10-year median is 29.66 vs. the industry median of 67.76, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.76, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current Days Sales Outstanding of 36.51 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Australian Clinical Labs and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current Days Sales Outstanding is 36.51, which is 23% above median its own 10-year median of 29.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Fairly Valued. The stock's GF Value™ is A$2.95, compared to a current price of A$2.71 — trading 8.1% below its estimated fair value. The current Days Sales Outstanding is 36.51, which is 23% above median its 10-year median of 29.66 and 46.1% below the Medical Diagnostics & Research industry median of 67.76. Australian Clinical Labs' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Days Sales Outstanding is 36.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.71 is trading 8.1% below its estimated GF Value™ of A$2.95.
GuruFocus considers Australian Clinical Labs to be Fairly Valued.
Key valuation signals for ASX:ACL:
Days Sales Outstanding: 36.51 (23% above median its 10-year median of 29.66)
GF Value™: A$2.95 vs. price of A$2.71 (8.1% below fair value)
Industry Position: 46.1% below the Medical Diagnostics & Research median (#29 of 202)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
73GF Score
Get the complete analysis for ASX:ACL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
